Boosting endocannabinoids reduced anxiety during nicotine withdrawal in rats but did not prevent physical symptoms
The FAAH inhibitor URB597 reduced withdrawal-induced anxiety in nicotine-dependent rats but did not prevent physical withdrawal signs, while brain anandamide levels fluctuated across multiple regions during withdrawal.
Quick Facts
What This Study Found
Rats made dependent on nicotine via transdermal patches for 7 days showed both physical and emotional withdrawal symptoms when patches were removed.
Physical (somatic) withdrawal signs appeared at 16 hours and emotional (affective) signs at 34 hours after patch removal. The researchers found that spontaneous nicotine withdrawal was accompanied by significant fluctuations in anandamide (an endocannabinoid) levels across the amygdala, hippocampus, hypothalamus, and prefrontal cortex. Levels of 2-AG, the other major endocannabinoid, were not significantly altered.
The FAAH inhibitor URB597, which boosts anandamide levels, reduced withdrawal-related anxiety at both doses tested (0.1 and 0.3 mg/kg) on two different anxiety measures. However, URB597 did not reduce physical withdrawal signs.
Key Numbers
Nicotine: 5.2 mg/rat/day for 7 days. Somatic signs at 16 hours, affective signs at 34 hours. URB597 at 0.1 and 0.3 mg/kg reduced anxiety. Anandamide fluctuated in amygdala, hippocampus, hypothalamus, and prefrontal cortex.
How They Did This
Controlled animal study in Wistar rats. Nicotine dependence induced via transdermal patches (5.2 mg/rat/day for 7 days). Withdrawal assessed by somatic signs, anxiety tests (elevated plus maze, shock-probe defensive burying), locomotion, and weight. Brain endocannabinoid levels measured by mass spectrometry. URB597 tested at 0.1 and 0.3 mg/kg i.p.
Why This Research Matters
The selective effect of endocannabinoid enhancement on emotional but not physical nicotine withdrawal suggested that boosting the endocannabinoid system could specifically target the anxiety component that often drives relapse.
The Bigger Picture
This research connected the endocannabinoid system specifically to the emotional aspects of nicotine withdrawal, suggesting that FAAH inhibitors could complement existing smoking cessation treatments by targeting withdrawal anxiety.
What This Study Doesn't Tell Us
Animal model using transdermal nicotine delivery that may differ from human smoking. Only one week of dependence induction. Brain endocannabinoid measurements were at specific time points. Translation to human smoking cessation uncertain.
Questions This Raises
- ?Could FAAH inhibitors help people quit smoking by reducing withdrawal anxiety?
- ?Would combining endocannabinoid enhancement with nicotine replacement be more effective than either alone?
Trust & Context
- Key Stat:
- URB597 reduced withdrawal anxiety but not physical symptoms
- Evidence Grade:
- Well-controlled animal study with multiple behavioral tests and neurochemical measurements, but limited to rodent models.
- Study Age:
- Published in 2011. Research on endocannabinoid-based smoking cessation approaches has continued.
- Original Title:
- Endocannabinoid regulation of acute and protracted nicotine withdrawal: effect of FAAH inhibition.
- Published In:
- PloS one, 6(11), e28142 (2011)
- Authors:
- Cippitelli, Andrea(2), Astarita, Giuseppe, Duranti, Andrea(2), Caprioli, Giovanni, Ubaldi, Massimo, Stopponi, Serena, Kallupi, Marsida, Sagratini, Gianni, Rodrìguez de Fonseca, Fernando, Piomelli, Daniele, Ciccocioppo, Roberto
- Database ID:
- RTHC-00474
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Could the endocannabinoid system help people quit smoking?
In rats, boosting endocannabinoid levels reduced the anxiety component of nicotine withdrawal. Since anxiety is a major driver of relapse, this approach could potentially complement existing cessation methods.
Does nicotine withdrawal affect the endocannabinoid system?
Yes. Nicotine withdrawal caused significant fluctuations in anandamide levels across brain regions including the amygdala and prefrontal cortex, suggesting the endocannabinoid system responds to nicotine dependence.
Read More on RethinkTHC
- 30-days-without-weed
- 6-months-sober-weed-what-to-expect
- 90-days-no-weed
- benefits-of-quitting-weed
- boredom-after-quitting-weed
- boredom-after-quitting-weed-nothing-fun
- cannabis-dependence-physical-psychological-addiction-science
- cannabis-perception-vs-evidence-gap
- cannabis-use-disorder-test
- creativity-without-weed-quitting-artist-musician
- cross-addiction-quit-weed-start-drinking
- hobbies-after-quitting-weed
- identity-after-quitting-weed
- is-weed-addictive
- is-weed-addictive-science
- leaving-stoner-culture-identity
- money-saved-quitting-weed-calculator
- one-year-sober-weed
- quitting-weed-and-alcohol
- quitting-weed-creativity
- quitting-weed-face-changes-skin
- quitting-weed-weight-loss-gain
- rehab-for-weed-addiction-necessary
- signs-of-cannabis-use-disorder
- weed-vape-pen-addiction
Cite This Study
https://rethinkthc.com/research/RTHC-00474APA
Cippitelli, Andrea; Astarita, Giuseppe; Duranti, Andrea; Caprioli, Giovanni; Ubaldi, Massimo; Stopponi, Serena; Kallupi, Marsida; Sagratini, Gianni; Rodrìguez de Fonseca, Fernando; Piomelli, Daniele; Ciccocioppo, Roberto. (2011). Endocannabinoid regulation of acute and protracted nicotine withdrawal: effect of FAAH inhibition.. PloS one, 6(11), e28142. https://doi.org/10.1371/journal.pone.0028142
MLA
Cippitelli, Andrea, et al. "Endocannabinoid regulation of acute and protracted nicotine withdrawal: effect of FAAH inhibition.." PloS one, 2011. https://doi.org/10.1371/journal.pone.0028142
RethinkTHC
RethinkTHC Research Database. "Endocannabinoid regulation of acute and protracted nicotine ..." RTHC-00474. Retrieved from https://rethinkthc.com/research/cippitelli-2011-endocannabinoid-regulation-of-acute
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.